Should I buy or sell Crinetics Pharmaceuticals stock right now?

12 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Crinetics Pharmaceuticals in the last year. There are currently 1 hold rating and 11 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" CRNX shares. View CRNX analyst ratings or view top-rated stocks .

What is Crinetics Pharmaceuticals' stock price target for 2024?

12 equities research analysts have issued 1 year target prices for Crinetics Pharmaceuticals' stock. Their CRNX share price targets range from $35.00 to $80.00. On average, they predict the company's share price to reach $54.17 in the next twelve months. This suggests a possible upside of 26.1% from the stock's current price. View analysts price targets for CRNX or view top-rated stocks among Wall Street analysts .

How have CRNX shares performed in 2024?

Crinetics Pharmaceuticals' stock was trading at $35.58 at the start of the year. Since then, CRNX shares have increased by 20.8% and is now trading at $42.97. View the best growth stocks for 2024 here .

When is Crinetics Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024. View our CRNX earnings forecast .

How were Crinetics Pharmaceuticals' earnings last quarter?

Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) issued its quarterly earnings results on Wednesday, February, 28th. The company reported ($0.90) EPS for the quarter, missing analysts' consensus estimates of ($0.89) by $0.01. Crinetics Pharmaceuticals had a negative net margin of 4,223.27% and a negative trailing twelve-month return on equity of 52.93%. The company's quarterly revenue was down 100.0% on a year-over-year basis. During the same period last year, the company posted ($0.84) EPS.

What ETFs hold Crinetics Pharmaceuticals' stock?

ETFs with the largest weight of Crinetics Pharmaceuticals (NASDAQ:CRNX) stock in their portfolio include ALPS Medical Breakthroughs ETF (SBIO) , Invesco Dorsey Wright Healthcare Momentum ETF (PTH) , SPDR S&P Biotech ETF (XBI) , First Trust Multi-Manager Small Cap Opportunities ETF (MMSC) , Virtus LifeSci Biotech Clinical Trials ETF (BBC) , BNY Mellon Innovators ETF (BKIV) , Direxion Daily S&P Biotech Bull 3x Shares (LABU) and First Trust BuyWrite Income ETF (FTHI) .

What is R. Scott Struthers, Ph.D.'s approval rating as Crinetics Pharmaceuticals' CEO?

6 employees have rated Crinetics Pharmaceuticals Chief Executive Officer R. Scott Struthers, Ph.D. on Glassdoor.com . R. Scott Struthers, Ph.D. has an approval rating of 100% among the company's employees. This puts R. Scott Struthers, Ph.D. in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 68.0% of employees surveyed would recommend working at Crinetics Pharmaceuticals to a friend.

What other stocks do shareholders of Crinetics Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Crinetics Pharmaceuticals investors own include SCYNEXIS (SCYX) , Sorrento Therapeutics (SRNE) , Aldeyra Therapeutics (ALDX) , G1 Therapeutics (GTHX) , Kura Oncology (KURA) , Otonomy (OTIC) , Selecta Biosciences (SELB) , TG Therapeutics (TGTX) , Arbutus Biopharma (ABUS) and Applied Genetic Technologies (AGTC) .

When did Crinetics Pharmaceuticals IPO?

Crinetics Pharmaceuticals (CRNX) raised $80 million in an initial public offering on Wednesday, July 18th 2018. The company issued 5,000,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan, Leerink Partners and Piper Jaffray served as the underwriters for the IPO.

Who are Crinetics Pharmaceuticals' major shareholders?

Crinetics Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Hennion & Walsh Asset Management Inc. (0.05%). Insiders that own company stock include Ajay Madan , Alan Seth Krasner, Coelho Rogerio Vivaldi, Dana Pizzuti, Jeff E Knight, Marc Wilson, Matthew K Fust , Perceptive Advisors Llc, Richard Scott Struthers , Stephanie Okey and Stephen F Betz . View institutional ownership trends .

How do I buy shares of Crinetics Pharmaceuticals?

Shares of CRNX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

Top-Rated StocksTop-Rated

NASDAQ:CRNX

Crinetics Pharmaceuticals (CRNX) Stock Price, News & Analysis

→ SHOCKING Crypto Leak… (From Crypto 101 Media) (Ad)

Free CRNX Stock Alerts

$42.97

-0.04 (-0.09%)

(As of 04/19/2024 ET)

Compare

Today's Range: $42.20
▼
$44.21
50-Day Range: $35.99
▼
$48.03
52-Week Range: $15.76
▼
$49.58

Volume: 624,655 shs
Average Volume: 781,688 shs
Market Capitalization: $2.99 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $54.17

Get Crinetics Pharmaceuticals alerts:

Crinetics Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating: Moderate Buy
2.92 Rating Score
Upside/Downside: 26.1% Upside
$54.17 Price Target
Short Interest: Bearish
7.05% of Shares Sold Short
Dividend Strength: N/A
Sustainability: -0.62
Upright™ Environmental Score
News Sentiment: 0.50
Based on 5 Articles This Week
Insider Trading: Selling Shares
$8.62 M Sold Last Quarter
Proj. Earnings Growth: Decreasing
From ($3.34) to ($3.55) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.21 out of 5 stars

Medical Sector

135th out of 911 stocks

Pharmaceutical Preparations Industry

44th out of 411 stocks

4.5

Analyst's Opinion

Consensus Rating
Crinetics Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.92, and is based on 11 buy ratings, 1 hold rating, and no sell ratings.
Amount of Analyst Coverage
Crinetics Pharmaceuticals has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

2.0

Short Interest

Percentage of Shares Shorted
7.05% of the outstanding shares of Crinetics Pharmaceuticals have been sold short.
Short Interest Ratio / Days to Cover
Crinetics Pharmaceuticals has a short interest ratio ("days to cover") of 6.1.
Change versus previous month
Short interest in Crinetics Pharmaceuticals has recently decreased by 2.00%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
Crinetics Pharmaceuticals does not currently pay a dividend.
Dividend Growth
Crinetics Pharmaceuticals does not have a long track record of dividend growth.

3.7

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Crinetics Pharmaceuticals has received a 46.37% net impact score from Upright. Crinetics Pharmaceuticals seems to create the most significant positive value in categories "Jobs", "Creating knowledge", and "Physical diseases". The positive contribution in the "Creating knowledge" impact category is false driven by its "Clinical research services for physical health", "Basic medical research services", and "Preclinical research services for physical health" products. See details.
Environmental Sustainability
The Environmental Impact score for Crinetics Pharmaceuticals is -0.62.

2.5

News and Social Media Coverage

News Sentiment
Crinetics Pharmaceuticals has a news sentiment score of 0.50. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
News Coverage This Week
MarketBeat has tracked 5 news articles for Crinetics Pharmaceuticals this week, compared to 4 articles on an average week.
Search Interest
14 people have searched for CRNX on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.
MarketBeat Follows
Only 6 people have added Crinetics Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -14% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Crinetics Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $8,621,177.00 in company stock.
Percentage Held by Insiders
Only 7.00% of the stock of Crinetics Pharmaceuticals is held by insiders.
Percentage Held by Institutions
98.51% of the stock of Crinetics Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0

Earnings and Valuation

Earnings Growth
Earnings for Crinetics Pharmaceuticals are expected to decrease in the coming year, from ($3.34) to ($3.55) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Crinetics Pharmaceuticals is -11.61, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Crinetics Pharmaceuticals is -11.61, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Crinetics Pharmaceuticals has a P/B Ratio of 5.32. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad DTI

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

Click here for the full story

About Crinetics Pharmaceuticals Stock (NASDAQ:CRNX)

Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. It is also developing CRN04894, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and Cushing's disease. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; identified investigational orally available somatostatin receptor type 3 targeted nonpeptide agonists for the treatment of autosomal dominant polycystic kidney disease; and developing thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease, as well as Oral GLP-1 and GIP nonpeptides for the treatment of diabetes and obesity. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.

CRNX Stock Price History

30 days | 90 days | 365 days | Advanced Chart

CRNX Stock News Headlines

April 18, 2024 | insidertrades.com

Insider Selling: Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Insider Sells 14,375 Shares of Stock

April 9, 2024 | insidertrades.com

Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) CEO Sells $2,013,560.67 in Stock

April 19, 2024 | Crypto 101 Media (Ad)

SHOCKING Crypto Leak…

A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.

April 3, 2024 | insidertrades.com

Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Director Stephanie Okey Sells 17,500 Shares

March 27, 2024 | insidertrades.com

Insider Selling: Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) COO Sells 32,359 Shares of Stock

March 23, 2024 | insidertrades.com

Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Insider Dana Pizzuti Sells 15,089 Shares

March 21, 2024 | insidertrades.com

Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) CFO Marc Wilson Sells 6,942 Shares

April 19, 2024 | americanbankingnews.com

Dana Pizzuti Sells 14,375 Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Stock

April 19, 2024 | Crypto 101 Media (Ad)

SHOCKING Crypto Leak…

April 14, 2024 | americanbankingnews.com

Crinetics Pharmaceuticals (NASDAQ:CRNX) Stock Price Down 7.8%

April 12, 2024 | finanznachrichten.de

Crinetics Pharmaceuticals, Inc.: Crinetics Pharmaceuticals Announces April 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

April 11, 2024 | finance.yahoo.com

Crinetics Pharmaceuticals Announces April 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

April 11, 2024 | globenewswire.com

Crinetics Pharmaceuticals Announces April 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

March 28, 2024 | investing.com

Crinetics Pharmaceuticals COO sells shares worth over $1.4 million

March 28, 2024 | insidermonkey.com

Insiders Are Dumping These 5 Healthcare Stocks

March 27, 2024 | finance.yahoo.com

Insider Sell: COO Jeff Knight Sells 32,359 Shares of Crinetics Pharmaceuticals Inc (CRNX)

March 22, 2024 | finance.yahoo.com

Director Matthew Fust Sells 60,000 Shares of Crinetics Pharmaceuticals Inc (CRNX)

March 22, 2024 | finance.yahoo.com

Insider Sell: Chief Medical and Development Officer Dana Pizzuti Sells 15,089 Shares of ...

March 21, 2024 | markets.businessinsider.com

Buy Rating Affirmed for Crinetics Pharmaceuticals on Paltusotine’s Clinical Success and Market Potential

March 21, 2024 | markets.businessinsider.com

Buy Rating Affirmed for Crinetics Pharmaceuticals Amid Impressive Paltusotine Trial Results

March 21, 2024 | finance.yahoo.com

Crinetics Pharmaceuticals Inc CFO Marc Wilson Sells 6,942 Shares

March 19, 2024 | marketwatch.com

Crinetics Pharmaceuticals Up on Positive Results for Acromegaly Drug Trial

March 19, 2024 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Crinetics Pharmaceuticals (CRNX) and Biogen (BIIB)

March 19, 2024 | benzinga.com

Endocrine Disease-Focused Crinetics Pharmaceuticals Stock Soars On Tuesday - Here's Why

March 19, 2024 | finance.yahoo.com

Crinetics Stock Jets 16% Higher, Reversing A Three-Week Decline On Its Phase 3 Win

March 19, 2024 | markets.businessinsider.com

Crinetics Pharma Reports Positive Results From Phase 3 Studies Of Paltusotine For Acromegaly

March 19, 2024 | reuters.com

Crinetics Pharma's hormonal disorder drug meets main goal in late-stage study

See More Headlines

Receive CRNX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Crinetics Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 2/28/2024
Today: 4/19/2024
Next Earnings (Estimated): 5/02/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:CRNX
CUSIP: N/A
CIK: 1658247
Web: www.crinetics.com
Phone: (858) 450-6464
Fax: N/A
Employees: 290
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $54.17
High Stock Price Target: $80.00
Low Stock Price Target: $35.00
Potential Upside/Downside: +26.1%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.92
Research Coverage: 12 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($3.70)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-214,530,000.00
Net Margins: -4,223.27%
Pretax Margin: -5,216.32%
Return on Equity: -52.93%
Return on Assets: -45.54%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 13.07
Quick Ratio: 13.07

Sales & Book Value

Annual Sales: $4.01 million
Price / Sales: 745.81
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $8.07 per share
Price / Book: 5.32

Miscellaneous

Outstanding Shares: 69,600,000
Free Float: 64,728,000
Market Cap: $2.99 billion
Optionable: Optionable
Beta: 0.63

A Guide To High-Short-Interest Stocks

MarketBeat's analysts have just released their top five short plays for April 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

Dr. R. Scott Struthers Ph.D. (Age 62)
Founder, President, CEO & Director
Comp: $870.69k
Dr. Stephen F. Betz Ph.D. (Age 58)
Founder & Chief Scientific Officer
Comp: $618.58k
Mr. Marc J. C. Wilson (Age 45)
Chief Financial Officer
Comp: $585.54k
Mr. James Hassard (Age 58)
Chief Commercial Officer
Comp: $513.34k
Dr. Dana Pizzuti M.D. (Age 68)
Chief Development Officer
Comp: $493.62k
Mr. Jeff E. Knight (Age 53)
Chief Operating Officer
Comp: $237.64k
Ms. Garlan Adams
General Counsel & Corporate Secretary
Ms. Adriana Cabre M.B.A.
Chief Human Resources Officer
Dr. Alan S. Krasner M.D. (Age 61)
Chief Medical Officer
Comp: $571.97k
Mr. Kevin Capps
Head of Intellectual Property

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

CRNX Stock Analysis - Frequently Asked Questions

Should I buy or sell Crinetics Pharmaceuticals stock right now?: 12 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Crinetics Pharmaceuticals in the last year. There are currently 1 hold rating and 11 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" CRNX shares.
View CRNX analyst ratings or view top-rated stocks.
What is Crinetics Pharmaceuticals' stock price target for 2024?: 12 equities research analysts have issued 1 year target prices for Crinetics Pharmaceuticals' stock. Their CRNX share price targets range from $35.00 to $80.00. On average, they predict the company's share price to reach $54.17 in the next twelve months. This suggests a possible upside of 26.1% from the stock's current price.
View analysts price targets for CRNX or view top-rated stocks among Wall Street analysts.
How have CRNX shares performed in 2024?: Crinetics Pharmaceuticals' stock was trading at $35.58 at the start of the year. Since then, CRNX shares have increased by 20.8% and is now trading at $42.97.
View the best growth stocks for 2024 here.
When is Crinetics Pharmaceuticals' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024.
View our CRNX earnings forecast.
How were Crinetics Pharmaceuticals' earnings last quarter?: Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) issued its quarterly earnings results on Wednesday, February, 28th. The company reported ($0.90) EPS for the quarter, missing analysts' consensus estimates of ($0.89) by $0.01. Crinetics Pharmaceuticals had a negative net margin of 4,223.27% and a negative trailing twelve-month return on equity of 52.93%. The company's quarterly revenue was down 100.0% on a year-over-year basis. During the same period last year, the company posted ($0.84) EPS.
What ETFs hold Crinetics Pharmaceuticals' stock?: ETFs with the largest weight of Crinetics Pharmaceuticals (NASDAQ:CRNX) stock in their portfolio include ALPS Medical Breakthroughs ETF (SBIO), Invesco Dorsey Wright Healthcare Momentum ETF (PTH), SPDR S&P Biotech ETF (XBI), First Trust Multi-Manager Small Cap Opportunities ETF (MMSC), Virtus LifeSci Biotech Clinical Trials ETF (BBC), BNY Mellon Innovators ETF (BKIV), Direxion Daily S&P Biotech Bull 3x Shares (LABU) and First Trust BuyWrite Income ETF (FTHI).

What is R. Scott Struthers, Ph.D.'s approval rating as Crinetics Pharmaceuticals' CEO?: 6 employees have rated Crinetics Pharmaceuticals Chief Executive Officer R. Scott Struthers, Ph.D. on Glassdoor.com. R. Scott Struthers, Ph.D. has an approval rating of 100% among the company's employees. This puts R. Scott Struthers, Ph.D. in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 68.0% of employees surveyed would recommend working at Crinetics Pharmaceuticals to a friend.
What other stocks do shareholders of Crinetics Pharmaceuticals own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Crinetics Pharmaceuticals investors own include SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), Aldeyra Therapeutics (ALDX), G1 Therapeutics (GTHX), Kura Oncology (KURA), Otonomy (OTIC), Selecta Biosciences (SELB), TG Therapeutics (TGTX), Arbutus Biopharma (ABUS) and Applied Genetic Technologies (AGTC).
When did Crinetics Pharmaceuticals IPO?: Crinetics Pharmaceuticals (CRNX) raised $80 million in an initial public offering on Wednesday, July 18th 2018. The company issued 5,000,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan, Leerink Partners and Piper Jaffray served as the underwriters for the IPO.
Who are Crinetics Pharmaceuticals' major shareholders?: Crinetics Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Hennion & Walsh Asset Management Inc. (0.05%). Insiders that own company stock include Ajay Madan, Alan Seth Krasner, Coelho Rogerio Vivaldi, Dana Pizzuti, Jeff E Knight, Marc Wilson, Matthew K Fust, Perceptive Advisors Llc, Richard Scott Struthers, Stephanie Okey and Stephen F Betz.
View institutional ownership trends.
How do I buy shares of Crinetics Pharmaceuticals?: Shares of CRNX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:CRNX) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial